Bank of America Bearish on TG Therapeutics After Earnings

Analysts see 49% downside for the biotech stock despite strong 2025 results.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

TG Therapeutics, Inc. (NASDAQ:TGTX) reported strong fourth-quarter and full-year 2025 financial results, including $616 million in total global revenue. However, Bank of America analyst Alec Stranahan reaffirmed a Sell rating on the stock with a $15 price target, reflecting a 49% downside from current levels. The firm cited concerns about the company's 2026 outlook, which includes $350 million in operating expenses plus an additional $100 million for subcutaneous manufacturing.

Why it matters

TG Therapeutics is a commercial-stage biopharmaceutical company focused on treatments for B-cell-mediated diseases. The bearish call from a major bank like Bank of America could impact investor sentiment and the stock price, despite the company's recent financial performance.

The details

For the full year 2025, TG Therapeutics reported net income of $447.2 million and total global revenue of $616 million, including $594 million from U.S. BRIUMVI net product sales and $12.8 million from Neuraxpharm. However, the company is projecting operating expenses of $350 million in 2026, plus an additional $100 million for subcutaneous manufacturing and start-up activities.

  • TG Therapeutics reported its Q4 2025 and full-year 2025 financial results on February 26, 2026.
  • Bank of America analyst Alec Stranahan reaffirmed a Sell rating on the stock with a $15 price target on February 27, 2026.

The players

TG Therapeutics, Inc.

A commercial-stage biopharmaceutical company focused on the development, commercialization, and acquisition of novel treatments for B-cell-mediated diseases.

Alec Stranahan

An analyst at Bank of America who reaffirmed a Sell rating on TG Therapeutics with a $15 price target.

Adam Waldman

The Chief Commercial Officer of TG Therapeutics, who commented on the company's outlook for the first quarter of 2026.

Got photos? Submit your photos here. ›

What they’re saying

“Turning to the first quarter … We expect U.S. revenue to grow sequentially over Q4 levels to approximately $185 million to $190 million.”

— Adam Waldman, Chief Commercial Officer (TG Therapeutics earnings call)

The takeaway

While TG Therapeutics reported strong financial results for 2025, the bearish outlook from Bank of America raises concerns about the company's ability to sustain its growth and profitability in the face of rising expenses. Investors will be closely watching the company's performance in 2026 to see if it can overcome these challenges.